Combination chemotherapy with gefitinib as first-line treatment in EGFR-mutated metastatic non-small cell lung cancer: A retrospective Indian experience

Background: Metastatic non-small cell lung cancer (NSCLC) harboring targetable epidermal growth factor receptor (EGFR) mutations is primarily treated with osimertinib. However, limited access to osimertinib in resource-constrained settings necessitates exploration of alternative treatment options. O...

Descrición completa

Detalles Bibliográficos

Principais autores:	Bharath Gangadharaiah, Prabhat G Roy, Aparna Sharma, Prabhat S Malik, Sachin Khurana, Deepam Pushpam, Deepali Jain
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wolters Kluwer Medknow Publications 2025-10-01
Series:	Cancer Research, Statistics, and Treatment
Assuntos:	chemotherapy egfr mutation gefitinib metastatic nsclc overall survival progression-free survival
Acceso en liña:	https://journals.lww.com/10.4103/crst.crst_270_24
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!